Skip to content

AIM round-up: Shield Therapeutics, GYG and Revolution Beauty


Another down day for London’s junior market with the AIM Index shedding just over nine points by the closing bell to sit at 909.33.

  • Shield Therapeutics +18%
  • Ascent Resources +16%
  • Velocys +14%
  • Revolution Beauty -59%
  • GYG -32%

Shield Therapeutics LON:STX topped the board on Tuesday although gains came in at a modest 18%. Yesterday’s statement regarding a $10m shareholder loan didn’t elicit much of a response at the time, but today’s move – off limited trade – could well be the market now factoring in the extra headroom available.

Ascent Resources LON:AST found itself in second place, some 16% ahead. An update this morning over revenue realisation and ongoing disputes seems to have been well received, with a meaningful uptick in volumes being seen. Shares in the £5m company now trade at levels not seen for a couple of months.

A notable mention for Velocys LON:VLS which added 14% on the day. Shares are now up by almost a third since the middle of July and Sustainable Aviation Fuel is certainly moving back onto the popular agenda. Is more news incoming?

Revolution Beauty LON:REVB was left down 59% and propping up the index today after a trading update. This saw expectations dialled down both for the near term and on into next year, with a number of factors being cited. These include the fact that two key growth markets – Russia and Ukraine – are now discounted. The stock only IPO’d just over a year ago and has lost 85% of its value since.

Superyacht painter GYG LON:GYG issued a trading update today. That suggests that full year expectations will be met and that a robust order book is in place for the second half of the year, but the company has also proposed delisting its stock from AIM. There’s a slew of factors here including the idea that the market isn’t fairly valuing the stock, but in light of today’s 32% sell off, there appear to be plenty of investors ready to jump ship.

Looking for great investing ideas? Sign up to our free newsletter.

Join us on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets

Back To Top